Investment-Based Crowdfunding for Biotech Companies: A Revolution with Risk
Source: Krist Werling, Bob Cohen and Michael Pilo, Genetic Engineering & Biotechnology News  (3/1/13)
"The second model is an equity-based or investment-based model and involves an actual investment in an entity that is pursuing a project. Members of the "crowd" that provide funding receive an ownership interest in the entity." More >

Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen
Source: George S. Mack of The Life Sciences Report  (2/28/13)
Gil Van Bokkelen has been in the stem cell industry for more than a decade. In recent years, the co-founder, chairman and chief executive officer of Athersys Inc. has stepped into regenerative medicine’s forefront, acting as a spokesman for the industry as well as demonstrating his love of science and passionately advocating for patients. In this interview with The Life Sciences Report, Van Bokkelen explores the past, present and future of the cell therapy and regenerative medicine industry, and outlines the investment possibilities in small companies on the sector's cutting edge. More >

What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic
Source: George S. Mack of The Life Sciences Report  (2/21/13)
Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation. More >

Why Does the Pentagon Want to Use This Penny Stock to Cure the Flu?
Source: Michael Robinson, Money Morning  (2/21/13)
"Fighting the flu is a big part of the roughly $30B vaccine industry. It's a battle that puts roughly 200,000 Americans in the hospital each year." More >

Like Peanut Butter and Chocolate: RNA Interference's Hot Partnership with Stem Cells
Source: Severine Kirchner, The Daily Reckoning  (2/19/13)
"Combining stem cell treatments with RNAi, the hottest technique in molecular biology, opens more possibilities and hopes than ever before of curing degenerative diseases." More >

Ram Selvaraju: Fall in Love with These Nine Biotech Stocks
Source: George S. Mack of The Life Sciences Report   (2/14/13)
When it comes to unearthing dynamic micro-cap biotech investment opportunities, Ram Selvaraju is a master. Selvaraju, managing director and head of healthcare equity research at Aegis Capital Corp., has selected nine names destined to attract investors willing to take calculated risks, which he shares in this interview with The Life Sciences Report. He also explains why he expects 2013 will be another good year for the biotech industry. More >

Big Growth Stories in Biotech
Source: George S. Mack of The Life Sciences Report  (2/14/13)
Bacteria are pure survivalists, and over billions of years they have evolved to produce ever-newer chemicals to protect themselves against other bugs. In the last 100 years they have begun to protect themselves against the antibiotics that humans have developed from those same bugs. But guess who's winning. In September 2012, the FDA said that more than 70% of the bacteria that produce hospital-associated infections (HAIs) are now resistant to at least one type of antibiotic—and in the year 2000 alone, almost 2 million (2M) cases of HAIs caused close to 99,000 deaths. Too bad the agency didn't give an updated number, because it's a certainty that things are not getting better. Unless a sustainable system is developed to counteract this tide, a catastrophe is just a matter of when, and not if. With not even a tiny bit of exaggeration, the appearance of a devastating superbug is a looming global crisis. More >

Obama's Call for R&D Investment May Boost Medical Research Budgets and Job Markets
Source: Genetic Engineering and Biotechnology News  (2/13/13)
"'If we want to make the best products, we also have to invest in the best ideas,' Obama contended." More >

Biotech May Be on a Roll, but Investors Still Need Innovation, Predictability
Source: Jennifer Boggs, BioWorld  (2/11/13)
"The past several years have seen investment enthusiasm move away from the supposedly risk-reduced reformulation-of-an-existing/generic-drug model. Innovation—new mechanisms, new targets—are what's going to attract the interest and the money." More >

Eight Biotech Growth Names: Greg Wade
Source: George S. Mack of The Life Sciences Report  (2/7/13)
The driving principle behind successful biotech investment for Managing Director and Senior Analyst Greg Wade of Wedbush Securities is to find companies with clinical assets that are of value to patients and hence to the marketplace. In this interview with The Life Sciences Report, Wade offers compelling cases for eight important names that span the market cap gamut. More >

Harry Dent: Roller Coasters, Megaphones, Addictions and Comas—What Kind of Economy Is This?
Source: JT Long of The Gold Report  (2/1/13)
"If I am right, and stocks crash again in late 2014 or early 2015, I want to buy in the healthcare sector in the U.S. and Europe, especially the most leveraged areas: biotech, medical devices and pharmaceuticals. The baby boomers will continue spending on healthcare and healthcare products, even as budgets get crimped by entitlement reductions." More >

Analysts' Watchlist 2013
Source: George S. Mack of The Life Sciences Report  (1/31/13)
More >

The Life Sciences Report Watchlist 2013
Source: George S. Mack of The Life Sciences Report   (1/31/13)
Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months. More >

The Life Sciences Report Watchlist 2013: The FDA and Stock Volatility
Source: George S. Mack of The Life Sciences Report  (1/31/13)
Various steps in the U.S. Food and Drug Adminstration's (FDA) oversight of drug development and approval provide investment opportunity. This brief overview, supplemental to the groundbreaking Life Sciences Report Watchlist 2013, provides insight into FDA events that typically cause movement in a drug company's stock. More >

Is This Drug the Key to an Alzheimer's Cure. . .and Profits?
Source: Michael Robinson, Money Morning  (1/30/13)
"This bit of breakthrough research could supercharge the race for the cure. There's even a way for you to invest." More >

Safest Way to Play Biotech
Source: Kevin Cook, Zacks Investment Research  (1/25/13)
For every company that hits the jackpot with a new marketable drug that makes it through the FDA gauntlets, there are a dozen stocks that run up on such hopes and then crash and burn when the trials fail. More >

Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured
Source: George S. Mack of The Life Sciences Report  (1/24/13)
Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider. More >

Stocks to Buy Now: Profit from Blockbuster New Drugs in 2013
Source: Don Miller, Money Morning   (1/21/13)
"Pharmaceutical firms logged 39 new drug approvals last year, and there are signs the trend could continue through 2013, according to Reuters." More >

The Pulse: Breaking News from the Life Sciences Sector
Source: Editors of The Life Sciences Report  (1/18/13)
To invest wisely in the life sciences, broad-spectrum knowledge is key. Such knowledge encompasses not only the analysis of industry experts featured in Streetwise Reports interviews, but also up-to-date news on cutting-edge research and development, the latest mergers and acquisitions and the drug development process, both within companies and in the regulatory arena. Our Twitter feed links you to the information you need to profit, both intellectually and financially. More >

Anything for a Buck: Jim Letourneau Looks to Canadian Biotech for Opportunity
Source: Daniel Levy of The Life Sciences Report  (1/17/13)
To avoid some of the "dysfunctional excess" of the energy and mining sectors, Jim Letourneau, self-described contrarian and founder and editor of the Big Picture Speculator, turns to investing in biotech. His focus is on Canadian companies, which he believes perform on a par with companies in the United States. In this interview with The Life Sciences Report, Letourneau describes what he looks for in a biotech investment and names some of his favorite companies. More >

FDA Begins Blazing Narrow Trail for Approval Shortcut
Source: Mari Serebrov, BioWorld  (1/15/13)
"As part of a goal to double the number of new drug approvals over the next decade, the President's Council of Advisors on Science and Technology recommended the shortcut to get much-needed therapies to well-defined populations for which there's a favorable risk-benefit balance." More >

The Pulse: Breaking News from the Life Sciences Sector
Source: Editors of The Life Sciences Report  (1/14/13)
To invest wisely in the life sciences, broad-spectrum knowledge is key. Such knowledge encompasses not only the analysis of industry experts featured in Streetwise Reports interviews, but also up-to-date news on cutting-edge research and development, the latest mergers and acquisitions and the drug development process, both within companies and in the regulatory arena. Our Twitter feed links you to the information you need to profit, both intellectually and financially. More >

Which Six Companies Are in Michael King's Oncology Wheelhouse?
Source: George S. Mack of The Life Sciences Report  (1/10/13)
JMP Securities Managing Director and Senior Biotechnology Analyst Michael King Jr. never recoils from the most sophisticated science. He's always been partial to oncology indications and to new technologies that disrupt old paradigms and usher in the new. King has the kind of stock-picking track record that merits attention, and in this interview with The Life Sciences Report, he brings six important ideas to the table for investors to consider. More >

Five Amazing Biotech Picks with Futuristic Technology
Source: George S. Mack of The Life Sciences Report  (1/10/13)
Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen Inc. (AMGN:NASDAQ) for $16 billion ($16B) for its antitumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen's (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow—Johnson & Johnson's (JNJ:NYSE) Remicade (infliximab) and Abbott Laboratories' (ABT:NYSE) Humira (adalimumab)—are blockbusters that could approach $20 billion in sales in 2012. More >

A Low-Risk Potential Double in Biotech
Source: Frank Curzio, Phase 1 Investor  (1/9/13)
"We could see at least 100% returns on this stock within 12–18 months. As we'll show you, based on our research, this forecast could prove extremely conservative." More >